Overview
LONGBIO-B (1779)
LongBio Pharma (Suzhou) Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, manufacture, and commercialization of biopharma...
- Open
- 59.000
- High
- 59.000
- Low
- 53.950
- Prev. Close
- 59.450
- Volume
- 72.50K
- Turnover
- 4.02M
- Avg Price
- 55.418
- Bid/Ask Ratio
- 16.13%
- Amplitude
- 8.49%
- 52wk High
- 165.900
- Volume Ratio
- 0.68
- Turnover Ratio
- 0.11%
- 52wk Low
- 43.200
- HK Mkt Cap
- 3.83B
- Market CapHKD
- 4.30B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -3.26
- EPSDynamic
- -4.07
- EPSStatic
- --
- BVPS
- 17.00
- P/B
- 3.31
- HK Shares
- 67.97M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 76.32M
- Min lot size
- 50
- Currency
- HKD
Daily Events
- Nov, 16
Longbio-B opened at HK$59.00, slid to HK$54.00 by 10:48 in the morning session and recovered to close at HK$57.55, down 3.2% on the day with an intraday range of more than 9%, as no fresh catalyst emerged and the stock kept digesting the 12%-15% single-day swings seen since late October and last week's 4.21% low-volume rebound. The fundamentals remain pre-revenue: Q2 2026 EPS was -HK$1.2563, a 26.21% wider loss year on year, net loss -HK$77.85 million, 50.84% deeper, and operating loss 78.98% larger, with ROE at -23.92%, PB 3.38x and PE -17.65x. The price sits below its MA20 of HK$58.28 and roughly 36% under the MA60 of HK$90.68, down 56.34% year to date and 65.31% below the 52-week high of HK$165.90 set on 29 June, while still 33.22% above the 3 November low of HK$43.20. Though turnover was only 0.10% on HK$3.63 million of value, thin liquidity amplifies the daily range.
- Nov, 12
LongBio-B (1779.HK) spiked then faded, touching HK$66.60 at 11:01 BJ, up more than 7% from the HK$62.00 previous close, before momentum drained and the stock slid to HK$60.95 at 15:59 and closed at HK$61.00, down 1.6% on 93,250 shares worth HK$5.89 million, with the HK$63.19 average price sitting above the close. That pattern extends a whipsaw stretch: single-session moves of +13% and -11% alternated last week even as the stock gained 10.8% over the week, and it only set a 52-week low in late October, so the price has rebounded off that floor but has given back most of this week's advance. Q2 2026 net loss of HK$77.85 million widened 50.8% year on year and the operating loss of HK$77.26 million widened 79.0%, losses expanding alongside the volatility, while the 100% transfusion-avoidance result for LP-005 in its Phase II PNH trial remains the main catalyst. Though the float is thin, so a few million Hong Kong dollars of turnover can amplify double-digit swings.
- Nov, 11
LONGBIO-B gapped up 6.6% to HK$65.00 at the open, then surrendered the gain to a 58.25 morning-session low before recovering to close at HK$61.60, up 1.07% on just HK$5.22 million turnover and a 0.13% turnover rate — a thin float amplifying two-way swings rather than fresh repricing. The shares have moved 43% and 12% in single sessions recently and have rebounded more than 42% off the HK$43.20 52-week low set on 3 November; they now sit marginally above the 20-day MA of HK$60.99 but far below the 60-day MA of HK$93.34, 62.87% under the HK$165.90 52-week high and down 53.26% year-to-date. Fundamentals have not turned: Q2 2026 net loss widened 50.84% year-on-year to HK$77.85 million, EPS -HK$1.2563, PE -18.89x, PB 3.62x, with no revenue disclosed, while LP-005's 100% transfusion avoidance in its Phase II PNH trial remains the pipeline narrative. Though the widening loss and empty top line leave the bounce looking like oversold repair.
- Nov, 10
Longbio-B rose 6.8% to HK$60.95, extending a rebound off its HK$43.2 52-week low on Nov 3 as interest in complement inhibitors stayed warm, with Phase II topline data for LP-005 in PNH and discussion that the US$10 billion complement market is only a starting point both still circulating. The session opened lower at HK$57.30, dipped to HK$57.10 and spiked to HK$61.35 by 09:32 BJ, then flattened near HK$59 before grinding higher through the afternoon to close at HK$60.95, close to the intraday high. Volume was just 39,600 shares worth HK$2.38 million, a 0.06% turnover rate, so thin liquidity amplified the range. Fundamentals remain pre-revenue: the Q2 2026 net loss was HK$77.85 million, 50.8% wider year on year, with an operating loss of HK$77.26 million, EPS of -HK$1.26 and PB at 3.58x. The stock is still down 53.8% YTD and trades below its MA20 of HK$62.40 and MA60 of HK$94.37, 63.3% under the HK$165.9 June high, while the thin tape keeps moves headline-driven.
- Nov, 9
LONGBIO-B staged a spike-and-fade session, opening at HK$57.00 and surging to HK$62.40 at 13:44 BJ—about 9.6% above the prior close of HK$56.95—before erasing the gain to close at HK$57.05, up 0.18%, on HK$14.2 million turnover and a 0.35% turnover rate. The intraday pulse followed recent Phase II PNH data for LP-005 showing 100% transfusion avoidance and rising attention on the complement-inhibitor space, extending the stock's volatile run after a 10.8% weekly gain. Fundamentals remain loss-making: Q2 2026 net loss was HK$77.85 million, 50.8% wider year on year, operating loss was HK$77.26 million, 79.0% wider, and EPS was -HK$1.2563, leaving little earnings support for the rebound. The stock is still 65.6% below its 52-week high of HK$165.9, down 56.7% YTD, and below its MA20 of HK$63.84 and MA60 of HK$95.36. Though the 10.8% weekly advance leaves room for profit-taking and turnover was only HK$14.2 million, the close near the day's low keeps focus on whether the recent data-driven interest can be sustained.
News
Market Movers · Longbio falls 7% in Hong Kong trading
Weekly Review · Weekly Recap | LONGBIO-B +4.21%, low-volume push near highs
Market Movers · LONGBIO-B rose approximately 7%
Market Movers · Lonbio climbs 8%
Market Movers · Longbio climbs 7%
Weekly Review · Weekly Recap | LONGBIO-B +10.8%, a wild week
